Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel plus pembrolizumab versus pembrolizumab alone in untreated advanced melanoma
2022-503140-41-00Phase 3Authorised
- Sponsor
- Iovance Biotherapeutics
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Lifileucel regimen + Keytruda with Keytruda monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2024; status: authorised.
02
Drugs
lifileucelpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-503140-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503140-41-00.